EVALUATION COMPARISON BETWEEN SINOVAC AND PFIZER VACCINE AMONG INDONESIAN CHILDREN AND TEENAGER UNDER 18 YEARS OLD

AZZAHROTUL QONA’AH IBNATUS SUTARDI; DIANA LAILA RAMATILLAH

doi:10.22159/ijap.2022.v14s2.44745

Authors

AZZAHROTUL QONA’AH IBNATUS SUTARDI Faculty Pharmacy, Universitas 17 Agustus 1945 Jakarta, Jl. Sunter Permai Raya, RT.11/RW.6, Sunter Agung, Tj. Priok, Kota Jakarta Utara-Daerah Khusus Ibukota Jakarta 14350, Indonesia
DIANA LAILA RAMATILLAH Faculty Pharmacy, Universitas 17 Agustus 1945 Jakarta, Jl. Sunter Permai Raya, RT.11/RW.6, Sunter Agung, Tj. Priok, Kota Jakarta Utara-Daerah Khusus Ibukota Jakarta 14350, Indonesia

DOI:

https://doi.org/10.22159/ijap.2022.v14s2.44745

Keywords:

Sinovac, Pfizer, Indonesian children and teenager under 18 y old

Abstract

Objective: To evaluate the comparison between the Sinovac vaccine and Pfizer vaccine for children and teenagers under 18 y in Indonesia and other factors that influence it.

Methods: The type of this research is observational with a cross-sectional design using convenience sampling for all children and teenager in Indonesia who has received the full dose of Sinovac and Pfizer vaccine.

Results: It was found that the efficacy for Sinovac and Pfizer vaccines was 99.5% and 99.75%, respectively. Other factors that influence the side effects and efficacy of vaccines are gender, age, and BMI, with a p-value of each variable<0.05.

Conclusion: There is a correlation between the type of vaccine, gender, age, and BMI with the efficacy and side effects of vaccination.

Downloads

Download data is not yet available.

References

Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53(3):371-2. doi: 10.1016/j.jmii.2020.02.011, PMID 32147409. Available from: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7102573/pdf/main.pdf.

Covid-19 task force. ANALYSIS OF COVID-19 Indonesia DATA. [Analisis data COVID-19 Indonesia] [internet]; 2021. Available from: https://covid19.go.id/p/berita/analisis-data-covid-19-indonesia-update-10-oktober-2021. [Last accessed on Oct 15 2021].

Anderson EJ, Campbell JD, Creech CB, Frenck R, Kamidani S, Munoz FM, Nachman S, Spearman P. Warp speed for coronavirus Disease 2019 (COVID-19) vaccines: why are children stuck in neutral? Clin Infect Dis. 2021;73(2):336-40. doi: 10.1093/cid/ciaa1425, PMID 32945335.

Novi J. Indonesian health minister to offer sinovac and pfizer vaccines for child jab. go.kompas.com [Internet]; 2021. Available from: https://go.kompas.com/read/2021/ 06/26/021716674/indonesian-health-minister-to-offer-sinovac-and-pfizer-vaccines-for-child-jab. [Last accessed on 16 Oct 2021].

Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, Lee GM, Talbot HK, Romero JR, Oliver SE. The advisory committee on immunization practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine- United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(49):1857-9. doi: 10.15585/mmwr.mm6949e1, PMID 33301429.

Jumroendararasame C, Panyakorn S, Othong R, Jumroendararasame A, Srimanan W, Tipparut K. Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report. Am J Ophthalmol Case Rep. 2021;24:101212. doi: 10.1016/j.ajoc.2021.101212.

Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, Kose S, Erdinc FS, Akalın EH, Tabak OF, Pullukcu H, Batum O, Simsek Yavuz S, Turhan O, Yıldırmak MT, Koksal İ, Taşova Y, Korten V, Yılmaz G, Celen MK, Altın S, Celik İ, Bayındır Y, Karaoglan İ, Yılmaz A, Ozkul A, Gur H, Unal S, CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-22. doi: 10.1016/S0140-6736(21)01429-X, PMID 34246358.

Smith AW, Mulholland K. 1st edtorials effectiveness of an inactivated SARS-CoV-2 Vaccine. 2021;946-8.

Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of covid-19 vaccines. Diagnostics (Basel). 2021;11(4):1-11. doi: 10.3390/ diagnostics11040579, PMID 33804914.

Ghasemiyeh P, Mohammadi Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int Immunopharmacol. 2021;100(June):108162. doi: 10.1016/j.intimp.2021.108162.

Bralianti PD, Akbar FN. COVID-19 vaccines and its adverse events following immunization (AEFI) in Indonesia. Avicenna J. 2021;2(1). Available from: http://journal.uinjkt.ac.id/index. php/amedj/article/view/19832/pdf#.

Updated DC. consolidated regional and global information on adverse events following immunization (aefi) against covid-19 and other updates thirteenth report official reports on pharmacovigilance PROGRAMS [internet]. Washington, DC; 2021. Available from: https://covid-19 pharmacovigilance.paho.org/img/recursos/60b944995929ee1db00300740.pdf. [Last accessed on 12 Feb 2022]

Ramatillah DL, Alam HF, Hamid Ipadeola M, Azhar S, Sulaiman S, Lukas S. Public knowledge about COVID-19 and its impact on the psychic condition of Indonesian. Society. 2021;48(8).

Zhao S, Lin Q, Ran J, Musa SS, Yang G. Since January 2020 elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. Prelim Estim Basic Reprod number Nov coronavirus China, from 2019 to 2020 A data-driven anal early phase outbreak; 2020 (Jan):214-7.

Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-8. doi: 10.1007/s00277-020-04019-0, PMID 32296910.

Umar A, Mohammed A, Tahir I, Abubakar SD, Alsabbagh M, Zian Z. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management; 2021;(Oct 2020). p. 1-12.

Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213. doi: 10.1007/s15010-020-01516-2, PMID 32886331.

Wan Y, Shang J, Graham R, Baric RS, Li F. Reconocimiento de receptores por el nuevo coronavirus de Wuhan: un analisis basado en estudios estructurales de una década del coronavirus del SARS. J Virol. 2020;94(7):1-9.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi: 10.1038/s41586-020-2012-7, PMID 32015507.

Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi: 10.1002/path.1570, PMID 15141377.

Li X. HHS Public Access. Physiol Behav. 2016;176(3):139-48.

Ramatillah DL, Gan SH, Sulaiman SAS, Puja D, Abubakar U, Jaber AAS, Lukas S, Jusnita N. Evaluation of treatment outcome for pneumonia among pre-vaccinated COVID-19 patients with/without comorbidity in a public hospital in Bengkulu, Indonesia. Vaccines. 2021;9(12):1411. doi: 10.3390/vaccines9121411, PMID 34960157.

Teotonio IMSN, de Carvalho JL, Castro LC, Nitz N, Hagstrom L, Rios GG, de Fatima Rodrigues de Oliveira M, Dallago BSL, Hecht M. Clinical and biochemical parameters of COVID-19 patients with prior or active dengue fever. Acta Trop. 2021;214:105782. doi: 10.1016/j.actatropica.2020.105782, PMID 33259817.

Daher A, Balfanz P, Cornelissen C, Muller A, Bergs I. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. 2020 (Jan).

Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, Zhang Z. Clinical characteristics of COVID-19 in children compared with adults in shandong province, China. Infection. 2020;48(3):445-52. doi: 10.1007/s15010-020-01427-2, PMID 32301099.

Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-research that is available on the COVID-19 resource center-including this for unrestricted research re-use a (Jan); 2020. p. 19-21.

Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. Int Immunopharmacol. 2021;101(PB). doi: 10.1016/j.intimp.2021.108351. PMID 108351.

Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. "Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety” [Response To Letter]. Infect Drug Resist. 2021;14:4501-2. doi: 10.2147/IDR.S344230, PMID 34737590.

Bukhari MH, Syed M, Zain S, Abad M, Ontario W. Guest editorial. The differences between traditional vaccines and RNA vaccines: safety, efficacy, reliability and future of COVID-19 vaccines. Ann King Edward Med Univ. 2021;27(2):172-82.

Elnaem MH, Mohd Taufek NH, Ab Rahman NS, Mohd Nazar NI, Zin CS, Nuffer W, Turner CJ. Covid-19 vaccination attitudes, perceptions, and side effect experiences in Malaysia: do age, gender, and vaccine type matter? Vaccines. 2021;9(10):1-15. doi: 10.3390/vaccines9101156, PMID 34696264.

Alghamdi A, Ibrahim A, Almutairi R, Joseph M, Alghamdi G, Alhamza A. A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: male versus female outcomes. J Adv Pharm Educ Res. 2021;11(2):51-6. doi: 10.51847/bCwca2qGfP.

Klugar M, Riad A, Mekhemar M, Conrad J, Buchbinder M, Howaldt HP, Attia S. Side effects of mrna-based and viral vector-based covid-19 vaccines among German healthcare workers. Biology (Basel). 2021;10(8):1-21. doi: 10.3390/biology10080752, PMID 34439984.

Alamer E, Alhazmi A, Qasir NA, Alamer R, Areeshi H, Gohal G, Qadri M, Hashem AM, Algaissi A. Side effects of COVID-19 Pfizer-BioNTech mRNA vaccine in children aged 12–18 years in Saudi Arabia. Vaccines. 2021;9(11):1-11. doi: 10.3390/ vaccines9111297.